Consequences of germline variation disrupting the constitutional translational initiation codon start sites of MLH1 and BRCA2: Use of potential alternative start sites and implications for predicting variant pathogenicity

Variants that disrupt the translation initiation sequences in cancer predisposition genes are generally assumed to be deleterious. However, few studies have validated these assumptions with functional and clinical data. Two cancer syndrome gene variants likely to affect native translation initiation were identified by clinical genetic testing: MLH1:c.1A>G p.(Met1?) and BRCA2:c.67+3A>G. In vitro GFP‐reporter assays were conducted to assess the consequences of translation initiation disruption on alternative downstream initiation codon usage. Analysis of MLH1:c.1A>G p.(Met1?) showed that translation was mostly initiated at an in‐frame position 103 nucleotides downstream, but also at two ATG sequences downstream. The protein product encoded by the in‐frame transcript initiating from position c.103 showed loss of in vitro mismatch repair activity comparable to known pathogenic mutations. BRCA2:c.67+3A>G was shown by mRNA analysis to result in an aberrantly spliced transcript deleting exon 2 and the consensus ATG site. In the absence of exon 2, translation initiated mostly at an out‐of‐frame ATG 323 nucleotides downstream, and to a lesser extent at an in‐frame ATG 370 nucleotides downstream. Initiation from any of the downstream alternative sites tested in both genes would lead to loss of protein function, but further clinical data is required to confirm if these variants are associated with a high cancer risk. Importantly, our results highlight the need for caution in interpreting the functional and clinical consequences of variation that leads to disruption of the initiation codon, since translation may not necessarily occur from the first downstream alternative start site, or from a single alternative start site. © 2013 Wiley Periodicals, Inc.

[1]  D. Rowe,et al.  Defective splicing of mRNA from one COL1A1 allele of type I collagen in nondeforming (type I) osteogenesis imperfecta. , 1993, The Journal of clinical investigation.

[2]  A. Spurdle,et al.  Sequence variant classification and reporting: recommendations for improving the interpretation of cancer susceptibility genetic test results , 2008, Human mutation.

[3]  Kiley J. Johnson,et al.  Functional assays for classification of BRCA2 variants of uncertain significance. , 2008, Cancer research.

[4]  Steven Gallinger,et al.  A Multifactorial Likelihood Model for MMR Gene Variant Classification Incorporating Probabilities Based on Sequence Bioinformatics and Tumor Characteristics: A Report from the Colon Cancer Family Registry , 2013, Human mutation.

[5]  N. de Wind,et al.  A cell‐free assay for the functional analysis of variants of the mismatch repair protein MLH1 , 2010, Human mutation.

[6]  Aung Ko Win,et al.  The Australasian Colorectal Cancer Family Registry , 2012, The Medical journal of Australia.

[7]  Xue-Qing Wang,et al.  Post-transcriptional Regulation of the GLI1 Oncogene by the Expression of Alternative 5′ Untranslated Regions* , 2001, The Journal of Biological Chemistry.

[8]  Predrag Radivojac,et al.  Calibration of Multiple In Silico Tools for Predicting Pathogenicity of Mismatch Repair Gene Missense Substitutions , 2013, Human mutation.

[9]  P. Senapathy,et al.  Origin of eukaryotic introns: a hypothesis, based on codon distribution statistics in genes, and its implications. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[10]  Etienne Rouleau,et al.  A guide for functional analysis of BRCA1 variants of uncertain significance , 2012, Human mutation.

[11]  A. de la Chapelle,et al.  Functional significance and clinical phenotype of nontruncating mismatch repair variants of MLH1. , 2005, Gastroenterology.

[12]  Jean-Philippe Vert,et al.  Guidelines for splicing analysis in molecular diagnosis derived from a set of 327 combined in silico/in vitro studies on BRCA1 and BRCA2 variants , 2012, Human mutation.

[13]  Cristina Bombieri,et al.  Disrupted posttranscriptional regulation of the cystic fibrosis transmembrane conductance regulator (CFTR) by a 5′UTR mutation is associated with a cftr‐related disease , 2011, Human mutation.

[14]  G. Inghirami,et al.  Initiation of translation from a downstream in-frame AUG codon on BRCA1 can generate the novel isoform protein ΔBRCA1(17aa) , 2000, Oncogene.

[15]  Hyunsoo Kim,et al.  Single-nucleotide polymorphisms inside microRNA target sites influence tumor susceptibility. , 2010, Cancer research.

[16]  Christopher D. Heinen,et al.  Pathological assessment of mismatch repair gene variants in Lynch syndrome: Past, present, and future , 2012, Human mutation.

[17]  Fergus J Couch,et al.  A Computational Method to Classify Variants of Uncertain Significance Using Functional Assay Data with Application to BRCA1 , 2011, Cancer Epidemiology, Biomarkers & Prevention.

[18]  N L Harris,et al.  Splice junctions, branch point sites, and exons: sequence statistics, identification, and applications to genome project. , 1990, Methods in enzymology.

[19]  S. Sharan,et al.  Mouse embryonic stem cell–based functional assay to evaluate mutations in BRCA2 , 2008, Nature Medicine.

[20]  A. Spurdle,et al.  Correlation of tumour BRAF mutations and MLH1 methylation with germline mismatch repair (MMR) gene mutation status: a literature review assessing utility of tumour features for MMR variant classification , 2012, Journal of Medical Genetics.

[21]  H T Lynch,et al.  New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative group on HNPCC. , 1999, Gastroenterology.

[22]  F. Couch,et al.  Prediction and assessment of splicing alterations: implications for clinical testing , 2008, Human mutation.

[23]  J. Trojan,et al.  Expression Defect Size among Unclassified MLH1 Variants Determines Pathogenicity in Lynch Syndrome Diagnosis , 2013, Clinical Cancer Research.

[24]  Preclinical S Tudy.  Characterization of BRCA1 and BRCA2 splicing variants: a collaborative report by ENIGMA consortium members , 2011 .

[25]  E. Grzybowska,et al.  Functional Impact of Sequence Alterations Found in BRCA1 Promoter/5'UTR Region in Breast/Ovarian Cancer Families from Upper Silesia, Poland , 2006, Hereditary cancer in clinical practice.

[26]  A. Spurdle.  Clinical relevance of rare germline sequence variants in cancer genes: evolution and application of classification models. , 2010, Current opinion in genetics & development.

[27]  Christopher D. Heinen,et al.  The predicted truncation from a cancer‐associated variant of the MSH2 initiation codon alters activity of the MSH2‐MSH6 mismatch repair complex , 2012, Molecular carcinogenesis.

[28]  A. Kochetov,et al.  Alternative translation start sites and hidden coding potential of eukaryotic mRNAs. , 2008, BioEssays : news and reviews in molecular, cellular and developmental biology.

[29]  Christopher D. Heinen,et al.  Determining the functional significance of mismatch repair gene missense variants using biochemical and cellular assays , 2012, Hereditary Cancer in Clinical Practice.

[30]  H. Brunner,et al.  Compound heterozygosity for two MSH2 mutations suggests mild consequences of the initiation codon variant c.1A>G of MSH2 , 2009, European Journal of Human Genetics.

[31]  C. Ban,et al.  Transformation of MutL by ATP Binding and Hydrolysis A Switch in DNA Mismatch Repair , 1999, Cell.

[32]  Paolo Peterlongo,et al.  Identification of fifteen novel germline variants in the BRCA1 3′UTR reveals a variant in a breast cancer case that introduces a functional miR‐103 target site , 2012, Human mutation.

[33]  T. Terwilliger,et al.  Rapid protein-folding assay using green fluorescent protein , 1999, Nature Biotechnology.

[34]  Xue-Qing Wang,et al.  5'-untranslated regions with multiple upstream AUG codons can support low-level translation via leaky scanning and reinitiation. , 2004, Nucleic acids research.

[35]  C. Béroud,et al.  Human Splicing Finder: an online bioinformatics tool to predict splicing signals , 2009, Nucleic acids research.

[36]  Xue-Qing Wang,et al.  Green fluorescent protein as a reporter in translational assays. , 2005, Analytical biochemistry.

[37]  Peter Bouwman,et al.  A high-throughput functional complementation assay for classification of BRCA1 missense variants. , 2013, Cancer discovery.

[38]  Douglas F Easton,et al.  Genetic evidence and integration of various data sources for classifying uncertain variants into a single model , 2008, Human mutation.